Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.

JAMA oncology - 1 Oct 2015

Yu Helena A, Tian Shaozhou K, Drilon Alexander E, Borsu Laetitia, Riely Gregory J, Arcila Maria E, Ladanyi Marc

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Adenocarcinoma of Lung
Share to Clinical Trials, Phase I as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Drug Substitution

Share to ErbB Receptors

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 26181354
DOI: 10.1001/jamaoncol.2015.1066
PMCID: PMC4665629

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain.PMID 26181354Read ↗

Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.Semantic proximity Read ↗

Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going.Semantic proximity Read ↗

[3rd generation's TKI in lung cancer non-small cell EGFR-mutated having acquired a secondary T790M resistance].Semantic proximity Read ↗

EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.Semantic proximity Read ↗

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-/second-generation EGFR-TKIsSemantic proximity Read ↗

Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer.Semantic proximity Read ↗

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.Semantic proximity Read ↗

EGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations.Semantic proximity Read ↗

Third generation EGFR TKIs: current data and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.